Previous close | 754.17 |
Open | 762.28 |
Bid | 761.00 x 800 |
Ask | 765.00 x 1000 |
Day's range | 758.25 - 769.68 |
52-week range | 323.26 - 800.78 |
Volume | |
Avg. volume | 3,213,986 |
Market cap | 724.652B |
Beta (5Y monthly) | 0.34 |
PE ratio (TTM) | 131.49 |
EPS (TTM) | 5.80 |
Earnings date | 30 Apr 2024 |
Forward dividend & yield | 5.20 (0.68%) |
Ex-dividend date | 14 Feb 2024 |
1y target est | 708.99 |
In this article, we will be taking a look at the 20 most overweight states in the US. If you do not wish to learn about the global obesity market, head straight to the 5 Most Overweight States in the US. In the United States, the issue of obesity remains a significant public health concern, […]
In this article, we will be taking a look at the 20 most owned stocks by hedge funds now. To skip our detailed analysis of the current stock market news, you can go directly to see the 5 Most Owned Stocks by Hedge Funds Now. Rate Cuts in June As the US economy continues to […]
The Food and Drug Administration’s approval of a liver drug from Madrigal Pharmaceuticals marks a turning point in the often-agonizing campaign to get a treatment onto the market for the condition known as MASH. It is also a reminder for investors that biopharma is opening other large markets aside from weight loss. For many investors, the whole story in biopharma these past 18 months has been the new obesity and Type 2 diabetes drugs from Eli Lilly and Novo Nordisk known as Zepbound and Wegovy.